原始来源记录
决策级顶线结果
Arcturus ARCT-032 II期中期数据显示I类CF患者黏液减少
6名I类CF成人患者接受10 mg ARCT-032治疗28天后的II期中期数据显示，4名参与者通过AI增强HRCT观察到黏液栓和黏液量减少。探索性FEV1分析提示肺功能有改善趋势。公司计划于2026年上半年启动一项最多20名CF参与者参加的为期12周的安全性和初步疗效研究。
关键事实
来源摘录
EX-99.1 2 e664913_ex99-1.htm EX-99.2 3 e664913_ex99-2.htm Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF participants planned to begin first half of 2026 SAN DIEGO--(BUSINESS WIRE)—Oct 21, 2025-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today an